

APOE genotyping

An important clue from the DNA

Clinical studies show that carriers of the APOE $\epsilon 4$ allele are at increased risk of potentially life-threatening side effects (ARIA, amyloid-related imaging abnormalities) in the form of brain oedema/bleeding under anti-beta-amyloid antibody treatment of Alzheimer's disease.¹

Therefore, APOE genotyping prior to anti-beta-amyloid antibody treatment to assess the individual ARIA risk is recommended.



EURORealTime APOE

- Real-time PCR-based multiplex test for precise typing of APOE alleles $\epsilon 2$, $\epsilon 3$ and $\epsilon 4$
- Compatible with various real-time PCR cyclers
- Automated output of results using the EURORealTime Analysis software

1. Filippi M, et al. Amyloid-Related Imaging Abnormalities and β -Amyloid-Targeting Antibodies: A Systematic Review. JAMA Neurol 79(3):291-304 (2022).

Learn more at
www.neuro-company.com
or contact us directly:
www.euroimmun.com/contact

